Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells

PA Witt-Enderby and ML Dubocovich

Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, Illinois 60611, USA.

The human ML1A melatonin receptor is expressed in the suprachiasmatic nucleus of the hypothalamus and is believed to regulate circadian rhythms. We report the kinetic characteristics and pharmacological profile of 2-[125I]iodomelatonin binding and the signaling pathway and agonist regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Association of 2- [125I]iodomelatonin binding was maximal by 1.5 hr at 37 degrees and fully dissociated on the addition of 1 microM melatonin. The binding of 2-[125I]iodomelatonin was saturable and of high affinity (KD = 74 +/- 14 PM, Bmax = 679 +/- 88 fmol/mg protein; three experiments). The pharmacological profile of various melatonin analogues revealed a profile (2-iodomelatonin > or = melatonin > N-acetyl serotonin > luzindole) characteristic of an ML1 subtype. Competition of melatonin for 2-[125I]iodomelatonin binding to the human ML1A receptor in lysed or intact cells resulted in biphasic curves revealing the existence of super high (approximately 20%) and high (approximately 80%) affinity states of the receptor. Guanosine-5'-0-(3-thio)triphosphate (100 PM-30 microM) when added alone inhibited 2-[125I]iodomelatonin binding (IC50 = 0.87 +/- 0.12 microM; three experiments), suggesting uncoupling of the receptor from G proteins. In addition, guanosine-5'-O-(3- thio)triphosphate (3 microM) produced a right-ward shift in both the super high and high binding melatonin affinities for 2- [125I]iodomelatonin resulting in monophasic curves. Melatonin (0.1 fM-1 nM) inhibited forskolin-induced cAMP formation in a concentration- dependent and biphasic manner. Low concentrations of melatonin (0.01 fM- 1 PM) inhibited forskolin (100 microM)-stimulated cAMP formation with an IC50 of 0.1 +/- 0.05 PM (four experiments) and a maximal inhibitory effect (26%) at 1 PM. Higher concentrations of melatonin (1 PM-1 nM) inhibited forskolin-induced cAMP formation with an IC50 of 64 +/- 1.8 PM (four experiments) and a maximal inhibition (74%) at 1 nM. Luzindole (1 microM), a competitive melatonin receptor antagonist, antagonized the effect of melatonin at the higher concentrations only (IC50 = 1.5 +/- 0.22 nM, pKB = -7.3; three experiments). Pretreatment with pertussis toxin completely abolished melatonin-mediated inhibition of forskolin-induced cAMP formation through these receptors. Pretreatment with various concentrations of melatonin (0.1 PM-1 microM) for different periods of time (1, 6, 18, and 24 hr) did not decrease 2- [125I]iodomelatonin binding. However, competition by melatonin for 2- [125I]iodomelatonin binding to cells pretreated with melatonin and washed was only to a single population of super high affinity sites (IC50 = 1.1 +/- 0.28 nM; three experiments) as revealed by monophasic curves. Cells pretreated with melatonin revealed a persistent inhibition (approximately 20%) of forskolin-induced cAMP formation that was not reversed by extensive washes (up to 1 hr) or when luzindole (1 microM) was added together with melatonin during pretreatment. These results suggest that tight binding of melatonin to the super high affinity state of the human ML1A melatonin receptor may be the mechanism by which low concentrations of circulating hormone in vivo regulates signaling in the suprachiasmatic nucleus of the hypothalamus.

Volume 50, Issue 1, pp. 166-174, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. K. Surratt, P. A. Witt-Enderby, D. A. Johnson, C. A. Anderson, J. D. Bricker, V. L. Davis, S. M. Firestine, and W. S. Meng Development of a Neuroscience-oriented "Methods" Course for Graduate Students of Pharmacology and Toxicology CBE Life Sci Educ, June 1, 2006; 5(2): 188 - 196. [Abstract] [Full Text] [PDF]

				M. J. GERDIN, M. I. MASANA, M. A. RIVERA-BERMUDEZ, R. L. HUDSON, D. J. EARNEST, M. U. GILLETTE, and M. L. DUBOCOVICH Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin FASEB J, November 1, 2004; 18(14): 1646 - 1656. [Abstract] [Full Text] [PDF]

				C. Torres-Farfan, H. G. Richter, A. M. Germain, G. J. Valenzuela, C. Campino, P. Rojas-Garcia, M. L. Forcelledo, F. Torrealba, and M. Seron-Ferre Maternal melatonin selectively inhibits cortisol production in the primate fetal adrenal gland J. Physiol., February 1, 2004; 554(3): 841 - 856. [Abstract] [Full Text] [PDF]

				F. Steffens, X.-B. Zhou, U. Sausbier, C. Sailer, K. Motejlek, P. Ruth, J. Olcese, M. Korth, and T. Wieland Melatonin Receptor Signaling in Pregnant and Nonpregnant Rat Uterine Myocytes as Probed by Large Conductance Ca2+-Activated K+ Channel Activity Mol. Endocrinol., October 1, 2003; 17(10): 2103 - 2115. [Abstract] [Full Text] [PDF]

				M. J. Gerdin, M. I. Masana, D. Ren, R. J. Miller, and M. L. Dubocovich Short-Term Exposure to Melatonin Differentially Affects the Functional Sensitivity and Trafficking of the hMT1 and hMT2 Melatonin Receptors J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 931 - 939. [Abstract] [Full Text] [PDF]

				C. Torres-Farfan, H. G. Richter, P. Rojas-Garcia, M. Vergara, M. L. Forcelledo, L. E. Valladares, F. Torrealba, G. J. Valenzuela, and M. Seron-Ferre mt1 Melatonin Receptor in the Primate Adrenal Gland: Inhibition of Adrenocorticotropin-Stimulated Cortisol Production by Melatonin J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 450 - 458. [Abstract] [Full Text] [PDF]

				M. I. Masana and M. L. Dubocovich Melatonin Receptor Signaling: Finding the Path Through the Dark Sci. Signal., November 6, 2001; 2001(107): pe39 - pe39. [Abstract] [Full Text] [PDF]

				C. S. Nelson, M. Ikeda, H. S. Gompf, M. L. Robinson, N. K. Fuchs, T. Yoshioka, K. A. Neve, and C. N. Allen Regulation of Melatonin 1a Receptor Signaling and Trafficking by Asparagine-124 Mol. Endocrinol., August 1, 2001; 15(8): 1306 - 1317. [Abstract] [Full Text] [PDF]

				L. J. McCawley, S. Li, M. Benavidez, J. Halbleib, E. V. Wattenberg, and L. G. Hudson Elevation of Intracellular cAMP Inhibits Growth Factor-Mediated Matrix Metalloproteinase-9 Induction and Keratinocyte Migration Mol. Pharmacol., July 1, 2000; 58(1): 145 - 151. [Abstract] [Full Text]

				F. Roka, L. Brydon, M. Waldhoer, A. D. Strosberg, M. Freissmuth, R. Jockers, and C. Nanoff Tight Association of the Human Mel1a-Melatonin Receptor and Gi: Precoupling and Constitutive Activity Mol. Pharmacol., November 1, 1999; 56(5): 1014 - 1024. [Abstract] [Full Text]

				R. De Salvia, M. Fiore, T. Aglitti, F. Festa, R. Ricordy, and R. Cozzi Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage Mutagenesis, January 1, 1999; 14(1): 107 - 112. [Abstract] [Full Text] [PDF]

				M. L. Dubocovich, K. Yun, W. M. Al-ghoul, S. Benloucif, and M. I. Masana Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms FASEB J, September 1, 1998; 12(12): 1211 - 1220. [Abstract] [Full Text]

				P. A. Witt-Enderby, M. I. Masana, and M. L. Dubocovich Physiological Exposure to Melatonin Supersensitizes the Cyclic Adenosine 3',5'-Monophosphate-Dependent Signal Transduction Cascade in Chinese Hamster Ovary Cells Expressing the Human mt1 Melatonin Receptor Endocrinology, July 1, 1998; 139(7): 3064 - 3071. [Abstract] [Full Text] [PDF]

				A. J. McArthur, A. E. Hunt, and M. U. Gillette Melatonin Action and Signal Transduction in the Rat Suprachiasmatic Circadian Clock: Activation of Protein Kinase C at Dusk and Dawn Endocrinology, February 1, 1997; 138(2): 627 - 634. [Abstract] [Full Text] [PDF]